Following a multi-agency pitch, Novo Nordisk India has appointed McCann Healthcare as the communication agency for its insulin portfolio.
‘Changing diabetes’ is the new Novo Nordisk initiative that aims at improving awareness levels in the context of insulin usage, and would take a concerted effort with its various stakeholders, in which the communication partner will play a significant role.
On the confirmation of the development, Vinay Ransiwal, Marketing Director, Novo Nordisk, said, “Right from the first presentation, McCann Healthcare impressed us with the clear and quick understanding of the issues, the use of systematic approach to arrive at insights, and finally demonstrating the ability to link them into an action plan that will be easy to implement.”
The need of good marketing strategy to create an impact in the market will be the main focus of the agency to highlight out the message.
Milan Agnihotri, Associate Vice President and Strategic Planning Director, McCann Healthcare, opined, “The importance of early insulin initiation in diabetes management is greatly under-recognised and further complicated by the various myths associated with it. We need to tackle the inertia and drive positive health seeking behaviour in this category.”
Sohan Shah, General Manager, McCann Healthcare, added, “We have put together a multi-faceted team to take this partnership forward. This team aligns with the Novo Nordisk’s mission of ‘Changing diabetes’ and of exemplifying insulin’s role in diabetes management. Our endeavour will be to collaborate with them, through marketing and communication initiatives, to fulfil this mission.”
Five agencies including the incumbent agency were invited for the pitch in July, and after two rounds, McCann Healthcare was shortlisted.